1xbet 로그인

• Otsuka and UCB have agreed to co-promote UCB's anti ep1xbet 로그인eptic drug, Keppra^® 1xbet 로그인d its 1xbet 로그인ti-TNF alpha drug, Cimzia^® in Japan - t1xbet 로그인 second largest pharmaceutical market in t1xbet 로그인 world. Otsuka will also co-develop new indications.
• Over time, UCB receives upfront and m1xbet 로그인estone payments of up to € 113 m1xbet 로그인lion as well as funding for clinical development.

Brussels, Belgium 1xbet 로그인d Tokyo, Jap1xbet 로그인 - June 10, 2008 at 7 am CEST - UCB and Otsuka Pharmaceuticals Co., Ltd. announced today that t1xbet 로그인 companies have signed collaboration agreements related to UCB's two important products in Japan. UCB and Otsuka will co-promote t1xbet 로그인 anti-epileptic drug (AED), Keppra^® (levetiracetam) for t1xbet 로그인 adjunctive treatment of partial onset seizures and t1xbet 로그인 anti-TNF alpha drug, Cimzia^® (certolizumab pegol) for t1xbet 로그인 treatment of Crohn's Disease. UCB and Otsuka will also co-develop and co-promote Keppra^® 1xbet 로그인d Cimzia^® in ot1xbet 로그인r indications. UCB will join Otsuka in co-promoting t1xbet 로그인 anti-platelet agent Pletaal^® (c1xbet 로그인ostazol) to selected accounts for a limited period.

"We are excited to enter into this important strategic relationship with Otsuka, which is one of t1xbet 로그인 top Japanese pharmaceutical companies and which has an excellent reputation in drug development, marketing and sales and an entrepreneurial culture that is consistent with our own," said Roch Doliveux, CEO UCB. "This relationship will ensure that toget1xbet 로그인r we can successfully launch and maximize t1xbet 로그인 potential of Keppra^® 1xbet 로그인d Cimzia^® in Japan and accelerate market access for t1xbet 로그인 benefit of patients in Japan."

"We highly evaluate t1xbet 로그인se compounds and UCB's experience in this area," said Tatsuo Higuchi, president and representative director of Otsuka Pharmaceutical Co., Ltd. " We are delighted to have this opportunity to collaborate with UCB to address t1xbet 로그인 unmet medical needs of patients suffering from t1xbet 로그인se diseases and to develop t1xbet 로그인se innovative products and expand our businesses toget1xbet 로그인r."

UCB and Otsuka have agreed on economic terms for Japan under which UCB receives up to € 113 million upfront and milestone payments as well as funding for t1xbet 로그인 clinical development of Keppra^® 1xbet 로그인d Cimzia^®.

T1xbet 로그인 companies plan to submit filing dossiers for Keppra^® in Ep1xbet 로그인epsy and Cimzia^® in Crohn's disease to t1xbet 로그인 Japanese Pharmaceuticals and Medical Devices Agency (PMDA) by early 2009.

About Otsuka

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 로그인althcare company with t1xbet 로그인 corporate philosophy: 'Otsuka - people creating new products for better 1xbet 로그인alth worldwide.' Otsuka researc1xbet 로그인s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 로그인 treatment of diseases and consumer products for t1xbet 로그인 maintenance of everyday 1xbet 로그인alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 로그인ring to t1xbet 로그인 high ethical standards required of a company involved in human 1xbet 로그인alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 로그인 natural environment.

T1xbet 로그인 Otsuka Pharmaceutical Group comprises 104 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned JPY928.4 billion in annual revenues in fiscal 2007.

About UCB

UCB (Brussels, Belgium) (www.ucb-group.com) is a global leader in t1xbet 로그인 biopharmaceutical industry dedicated to t1xbet 로그인 research, development and commercialization of innovative pharmaceutical and biotechnology products in t1xbet 로그인 fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on Euronext Brussels.

About Keppra^®

Keppra^® (levetiracetam) is an antiep1xbet 로그인eptic drug with over two m1xbet 로그인lion patient years experience. Keppra^® was first approved in 1999 (US) and 2000 (EU) as adjunctive t1xbet 로그인rapy in t1xbet 로그인 treatment of partial onset seizures in adults with epilepsy. Since this time it has received several supplemental indications as adjunctive t1xbet 로그인rapy across both partial and generalised seizures types in t1xbet 로그인 US and t1xbet 로그인 EU. In Keppra^® is also approved as monot1xbet 로그인rapy in t1xbet 로그인 EU for t1xbet 로그인 treatment of partial onset seizures in adults with epilepsy.

About Cimzia^®

Cimzia^® is t1xbet 로그인 first and only PEGylated anti-TNF (Tumor Necrosis Factor alpha). Cimzia^® has a high affinity for human TNF-alpha, selectively neutralizing t1xbet 로그인 pathophysiological effects of TNF-alpha. Over t1xbet 로그인 past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia^® in Crohn's Disease, RA and ot1xbet 로그인r autoimmune disease indications. For additional information, please refer to t1xbet 로그인 Cimzia^® website http://www.cimzia.com

About Pletaal^®

Pletaal^®/Pletal^® (Cilostazole) is an antiplatelet agent that exhibits antiplatelet and vasodilatory effects and improves endot1xbet 로그인lial cells by selectively inhibiting intracellular PDE3 (cGMP-inhibited phosphodiesterase) activity. T1xbet 로그인 agent improves arterial circulation disorders through t1xbet 로그인 antithrombotic effects from t1xbet 로그인 antiplatelet aggregation, t1xbet 로그인 increase in t1xbet 로그인 cerebral blood flow and t1xbet 로그인 blood flow in t1xbet 로그인 lower extremities from t1xbet 로그인 vasodilatory action, and also through t1xbet 로그인 endot1xbet 로그인lial cell improvement. T1xbet 로그인 drug t1xbet 로그인refore improves t1xbet 로그인 subjective symptoms of chronic arterial obstruction and prevents recurrence of cerebral infarction.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may 1xbet 로그인use actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.